Evaluation of Nonfasting Tests to Screen for Childhood and Adolescent Dysglycemia

Joyce M. Lee, MD, MPH1,2 Achamyelesh Gebremariam, MS2 En-Ling Wu, BA3 Jennifer LARose, BS4 James G. Gurney, PhD5

OBJECTIVE—To assess performance of nonfasting tests to screen children for dysglycemia (prediabetes or diabetes).

RESEARCH DESIGN AND METHODS—This was a cross-sectional study of 254 overweight or obese (BMI ≥85th percentile) children aged 10–17 years. Subjects came for two visits to a clinical research unit. For visit one, they arrived fasting and a 2-h glucose tolerance test and HbA1c, and fructosamine testing were performed. For visit two, they arrived nonfasting and had a random plasma glucose, a 1-h 50-g nonfasting glucose challenge test (1-h GCT), and urine dipstick performed. The primary end point was dysglycemia (fasting plasma glucose ≥100 mg/dL or a 2-h postglucose ≥140 mg/dL). Test performance was assessed using receiver operating characteristic (ROC) curves and calculations of area under the ROC curve.

RESULTS—Approximately one-half of children were female, 59% were white, and 30% were black. There were 99 (39%) cases of prediabetes and 3 (1.2%) cases of diabetes. Urine dipstick, HbA1c, urinalysis, fructosamine, a nonfasting glucose challenge test (1-h GCT), and random plasma glucose displayed poor discrimination for identifying children with dysglycemia. Both random glucose (AUC 0.66 [0.60–0.73]) and 1-h GCT (AUC 0.68 [0.61–0.74]) had better levels of test discrimination than HbA1c or fructosamine.

CONCLUSIONS—HbA1c had poor discrimination, which could lead to missed cases of dysglycemia in children. Random glucose or 1-h GCT may potentially be incorporated into clinical practice as initial screening tests for prediabetes or diabetes and for determining which children should undergo further definitive testing.

Diabetes Care 34:2597–2602, 2011

Rates of type 2 diabetes in the U.S. pediatric population are rising (1,2). Because type 2 diabetes can be asymptomatic at diagnosis and requires tight glycemic, blood pressure, and lipid control to delay the onset of microvascular and macrovascular complications, screening for type 2 diabetes in children is endorsed by the American Diabetes Association (ADA) and the American Academy of Pediatrics (3,4). There is also increasing interest in screening for prediabetes in the pediatric population (5,6), given its increasing prevalence (7) and the documented link between prediabetes in childhood and development of diabetes in young adulthood (8).

The ADA guidelines (3) recommend that children with a BMI ≥85th percentile for age and sex and additional risk factors should be screened every 2 years starting at age 10 years or at onset of puberty and that either a fasting plasma glucose (FPG) or a 2-h glucose tolerance test be performed. However, these recommendations were based on expert opinion and were not evidence based, as acknowledged by the ADA in its Position Statement.

Both FPG and 2-h postload glucose have traditionally been used as the gold standard tests for diagnosing diabetes, but both tests require that the individual be fasting, which is an important barrier to screening. Studies have found that only a minority (4–21%) of pediatric providers in the primary care setting have screening practices consistent with the ADA guidelines (9,10) and instead use nonfasting tests, such as HbA1c, random glucose, or urinalysis.

Furthermore, in 2009, the screening and diagnosis landscape changed when an international expert committee of individuals from the ADA and their international counterparts recommended that HbA1c be exclusively used for the diagnosis of diabetes with eventual phase out of additional glucose measurements such as FPG and the 2-h postload glucose (11).

Despite the frequent use of nonfasting tests by physicians in clinical practice and the recent guideline advocating HbA1c as a diagnostic test for diabetes among children, there is a critical lack of data about the performance of nonfasting tests in children. Therefore, the objective of our study was to assess the test performance of nonfasting screening tests, including HbA1c, urinalysis, fructosamine, a nonfasting 1-h glucose challenge test (1-h GCT), and a random blood glucose for identifying adolescents aged 10–17 years with dysglycemia. Empiric information about test performance for nonfasting diabetes tests is critical for the development of evidence-based screening recommendations for prediabetes and diabetes in overweight and obese children.

RESEARCH DESIGN AND METHODS—Our study population consisted of a convenience sample of overweight or obese adolescents aged 10–17 years without known diabetes. The majority of children were recruited from pediatric primary care clinics (85%) with a smaller fraction (15%) from pediatric specialty clinics in the southeast Michigan.
Nonfasting screening tests for dysglycemia

area. Patients and families were recruited by research assistants in the clinic or responded to flyers posted in pediatric clinics and received an incentive for participating in the study. We excluded those who were pregnant and those who were on medications known to affect glucose metabolism.

Children came in for two visits to the Michigan Clinical Research Unit, where a history and physical exam were performed. For the first visit, they had a formal 2-h oral glucose tolerance test (OGTT) performed. They were fasting for a minimum of 12 h and had an intravenous catheter placed. Blood was drawn at baseline and every 30 min up to 2 h following a glucose ingestion of 1.75 g/kg to a maximum of 75 g. Testing was also conducted for HbA1c and fructosamine. Within 1–3 weeks, participants returned for a second visit in a nonfasting state. They had a random glucose test (glucose measured in a nonfasting state), a 1-h GCT (glucose measured 1 h after ingestion of 50 g of glucose in a nonfasting state), and urinalysis (measured 1 h after ingestion of 50 g glucose). We elected to use a uniform 50-g challenge (which was well tolerated by the children), given that it would be difficult for primary care providers to calculate weight-specific doses. Visit one was generally conducted in the morning, with mean time of administration of glucose 9:34 A.M., and visit two was generally conducted in the afternoon, with random plasma glucose (PG) drawn at a mean time of 1:23 P.M. The majority of families did not have access to their results until after visit two; therefore, it is unlikely that the children and their families were sensitized to the issue of diabetes.

Glucose was measured using the glucose hexokinase method, and HbA1c was measured using an NGSP-certified assay in whole blood (Pointe Scientific) using anti-human HbA1c monoclonal antibody. Glucose, fructosamine, and HbA1c were all measured using the Cobas Mira Plus Chemistry Analyzer. Urine dipstick was performed using Chemstrip 10 strips manufactured by Roche. Laboratory measurements were performed by the Michigan Diabetes Research and Training Center Core Laboratories.

Study definitions

Measured height and weight were converted to BMI percentiles according to the 2000 Centers for Disease Control and Prevention growth curves (12). Overweight was defined as an age-, sex-, and race-specific BMI ≥85th and <95th percentile, and obesity was similarly defined as a BMI ≥95th percentile. We elected to use definitions of prediabetes and diabetes based on the FPG and the 2-h PG. We acknowledge limitations of these definitions, given studies which have shown low concordance (13) and lack of reproducibility (14,15). However, these definitions have traditionally been used throughout the pediatric literature (16–18), which is important for comparison of our data with previous literature. Furthermore, these tests were the ADA-recommended gold standard tests prior to 2010 (19). With the 2010 revised guidelines (20), individuals can still be classified as having prediabetes or diabetes according to these tests, even if they are not recommended as first-line tests.

Based on the OGTT, considered the gold standard test, normal glucose metabolism was defined as a 2-h postload glucose level of <140 mg/dL and an FPG of <100 mg/dL. Prediabetes was defined as either impaired glucose tolerance (IGT) (2-h postload glucose ≥140 and <200 mg/dL) or impaired fasting glucose (IFG) (FPG ≥100 and <126 mg/dL). Diabetes was defined as a 2-h postload glucose ≥200 mg/dL or FPG ≥126 mg/dL (19). Because of the low number of children with diabetes (n = 3), we created a combined outcome of dysglycemia (prediabetes or diabetes) (n = 102). Any evidence of glucose (trace or above) was classified as a positive urine dipstick result. In sensitivity analyses, we assessed the degree to which the nonfasting tests predicted IGT and IFG separately, and we provide results of testing for prediabetes alone, excluding those from the three individuals with diabetes (Supplementary Fig. 1C).

We assessed sensitivity, specificity, positive likelihood ratio, and positive and negative predictive values at various thresholds of each test, with the exception of the urine dipstick test, for which the result was either positive or negative. Positive likelihood ratios represent the ratio of sensitivity to 1-specificity; positive predictive value represents the probability of having the disease given a positive test result, and negative predictive value represents the probability of not having the disease given a negative test result. We then used receiver operating characteristic (ROC) analysis, which assesses the trade-offs between sensitivity and specificity at various test cutoffs or thresholds for each of the four remaining nonfasting tests. We tested the homogeneity of ROC areas across the nonfasting tests.

Previous studies in adults have found that the number of hours since the last meal (postprandial time) can impact nonfasting test performance (21). Therefore, we also assessed test performance in children by postprandial time (<2 h and ≥2 h) and by time of day (A.M. vs. P.M.) for random glucose and 1-h GCT.

The prevalence of type 2 diabetes in children is low (22). For example, the recent SEARCH for Diabetes in Youth study used gold standard methods for defining type 2 diabetes and reported a prevalence of 0.04% among U.S. adolescents aged 10–19 years in 2001 (23). Therefore, our sample size calculations were based on the combined outcome of prediabetes and diabetes. Our goal was a sample size of 250, assuming a 35% prevalence of prediabetes in the population, a sensitivity of 65%, and a width of 20% for a two-sided 95% CI. Statistical analyses were performed using Stata 10.0 (Stata-Corp, College Station, TX). Sample sizes stratified by race and sex were too small to make reasonable conclusions. This study was approved by the University of Michigan institutional review board.

RESULTS—Table 1 shows demographic characteristics of the 254 children in the study. There were slightly more female than male subjects, and close to one-third of the population was black. There was a higher proportion of obese children in the sample compared with overweight children. Of the population, 39% had prediabetes, and only 1.2% of children were classified as having diabetes. Although there was a higher prevalence of prediabetes in blacks (46%) compared with whites (36%) and male subjects (44.6%) compared with female subjects (36.1%), these comparisons were not statistically significant. The majority of children in the study were pubertal, regardless of glucose tolerance status.

Table 2 shows performance results of the five different nonfasting tests for identifying children with dysglycemia. Urine dipstick, for which there was only one threshold (positive vs. negative), had a very low sensitivity despite a high specificity. For the other tests, higher test thresholds resulted in a lower sensitivity and a higher specificity and lower test thresholds in a higher sensitivity and a lower specificity.

Figure 1A–D displays ROC curves at various cutoffs for each of the four remaining nonfasting tests. Discrimination was equally poor for HbA1c and fructosamine,
Table 1—Characteristics of the study population

|                | Overall population | Normal glucose tolerance | IFG only | IGT only | IFG and IGT | Diabetes |
|----------------|-------------------|--------------------------|----------|----------|-------------|----------|
| n              | 254               | 152                      | 46       | 36       | 17          | 3        |
| Age (years), mean (SD) | 13.6 (2.1) | 13.6 (2.2) | 14.0 (1.9) | 13.5 (2.0) | 13.0 (1.9) | 12.1 (2.2) |
| Sex            |                   |                          |          |          |             |          |
| Female         | 52.4 (133)        | 55.9 (85)                | 45.7 (21) | 55.6 (20) | 35.3 (6)    | 33.3 (1) |
| Male           | 47.6 (121)        | 44.1 (67)                | 54.3 (25) | 44.4 (16) | 64.7 (11)   | 66.7 (2) |
| Race           |                   |                          |          |          |             |          |
| White          | 50.1 (150)        | 63.2 (96)                | 47.8 (22) | 50.0 (18) | 70.6 (12)   | 66.7 (2) |
| Black          | 29.9 (76)         | 27.0 (41)                | 45.7 (21) | 33.3 (12) | 5.9 (1)     | 33.3 (1) |
| Other          | 11.0 (28)         | 9.8 (15)                 | 6.5 (3)  | 16.7 (6) | 23.5 (4)    | —        |
| Weight status  |                   |                          |          |          |             |          |
| Overweight (BMI ≥85th percentile and <95th percentile) | 21.6 (55) | 25.7 (39) | 19.6 (9) | 8.3 (3) | 17.7 (3) | 33.3 (1) |
| Obese (BMI ≥95th percentile) | 78.4 (199) | 74.3 (113) | 80.4 (37) | 91.7 (33) | 82.3 (14) | 66.7 (2) |
| Family history of type 2 diabetes* | Yes | 76.2 (166) | 70.5 (93) | 84.2 (32) | 81.3 (26) | 92.9 (13) | — |
|                | No                | 23.8 (52)                | 29.5 (39) | 15.8 (6) | 18.7 (6)    | 7.1 (1)  | 100.0 (2) |
| Tanner stage** | Median (range)    | 4 (1–5)                  | 4 (1–5)  | 4 (1–5)  | 4 (1–5)     | 3 (1–5)  | 1.5 (1–2) |
| Prepubertal    | 6.6 (13)          | 6.8 (8)                  | 2.9 (1)  | 6.7 (2)  | 8.3 (1)     | 50.0 (1) |
| Pubertal (Tanner stage 2 or higher) | 93.4 (184) | 93.2 (110) | 97.1 (34) | 93.3 (28) | 91.7 (11) | 50.0 (1) |

Data are % (n) unless otherwise noted. *For those with self-reported family history. **For those with self-reported pubertal measures.

as indicated by relatively low likelihood ratios across thresholds and low values for area under the curve (AUC). In contrast, random glucose and 1-h GCT had levels of test discrimination closer to an acceptable range. Compared with HbA1c, there was no significant difference in AUC for fructosamine, but AUC was significantly higher for both random glucose (P = 0.01) and 1-h GCT (P < 0.01). We did not find any differences in test performance by postprandial time or by time of day (A.M. vs. P.M.) for the 1-h GCT or the random glucose (data not shown).

ROC curves were also created for identifying individuals with IGT and IFG as separate outcomes (Supplementary Fig. IA and B). Although AUC appeared to be quite similar for most tests, AUC for the 1-h GCT was substantially higher to be quite similar for most tests, AUC was significantly higher for both random glucose and 1-h GCT had levels of discriminatory power for identifying IGT and IFG (0.58), which is consistent with the finding of high sensitivity for identifying overweight or obese children with diabetes (HbA1c ≥6.5%) and prediabetes (HbA1c 5.7–6.4%). We found that HbA1c had less than acceptable test performance for children with dysglycemia. Although the majority of patients in our study had prediabetes, two of three children with diabetes would have been missed using the ADA recommendation of 6.5%, with HbA1c levels of 5.1 and 5.2%.

Our findings are consistent with recent studies of HbA1c test performance in children. Using a nationally representative sample from National Health and Nutrition Examination Survey (NHANES) 1999–2006 (24), we found that an HbA1c threshold of 6.0% had low sensitivity for identifying overweight or obese children with prediabetes; sensitivity was 1.1% for identifying children with IFG (based on an FPG ≥100 mg/dL) and 0% for identifying children with IGT (based on a 2-h postload glucose ≥140 mg/dL), despite having high specificity for both outcomes (99%). In addition, the AUC for HbA1c was relatively low at 0.61 for predicting IFG and 0.53 for predicting IGT. Another study of a large cohort of obese children has also reported lower sensitivity for HbA1c (25). In contrast, adult studies have shown higher sensitivities for dysglycemia in the range of (20–25%) and higher levels of discrimination (26).

To our knowledge, the HbA1c guidelines have yet to be reviewed or endorsed by pediatric organizations such as the American Academy of Pediatrics. If the guidelines were to be endorsed by these organizations, this would most likely result in increased uptake of the test by providers, which could potentially lead to significant proportion of missed cases of prediabetes and diabetes in the pediatric population.

Either the nonfasting 1-h GCT or the random glucose represent promising screening tests used in the clinical setting for identifying dysglycemia in a population of overweight and obese adolescents and found reasonable test performance for the 1-h GCT and the random glucose. In contrast, test performance for HbA1c, fructosamine, and urinalysis was poor. Our findings have direct relevance for future recommendations for screening and diagnosis of dysglycemia among overweight and obese children and adolescents.

The poor test performance of HbA1c is notable given recent changes in diagnostic guidelines for prediabetes and diabetes (11), which advocate the use of HbA1c for identifying children and adults with diabetes (HbA1c ≥6.5%) and prediabetes (HbA1c 5.7–6.4%). We found that HbA1c had less than acceptable test performance for children with dysglycemia. Although the majority of patients in our study had prediabetes, two of three children with diabetes would have been missed using the ADA recommendation of 6.5%, with HbA1c levels of 5.1 and 5.2%.

CONCLUSIONS—We systematically evaluated a variety of nonfasting screening tests used in the clinical setting for identifying dysglycemia in a population of overweight and obese adolescents and found reasonable test performance for the 1-h
Nonfasting screening tests for dysglycemia

Table 2—Test characteristics of HbA1c, urinalysis, fructosamine, random glucose, and 1-h GCT for predicting dysglycemia (prediabetes or diabetes)

| Threshold       | Sensitivity (%) | Specificity (%) | Positive likelihood ratio | Positive predictive value (%) | Negative predictive value (%) |
|-----------------|-----------------|-----------------|---------------------------|-------------------------------|------------------------------|
| Urinalysis (n = 218) |                 |                 |                           |                               |                              |
| Positive        | 2               | 97              | 0.75                      | 34                            | 59                           |
| HbA1c (%)       |                 |                 |                           |                               |                              |
| (AUC 0.54 [95% CI 0.47–0.61]; n = 254) |                 |                 |                           |                               |                              |
| 4.4             | 100             | 0               | 1.00                      | 40                            |                              |
| 4.7             | 99              | 2               | 1.01                      | 41                            | 75                           |
| 5.0             | 93              | 9               | 1.03                      | 41                            | 67                           |
| 5.3             | 70              | 36              | 1.08                      | 42                            | 63                           |
| 5.5             | 45              | 57              | 1.04                      | 41                            | 60                           |
| 5.7             | 32              | 74              | 1.23                      | 45                            | 62                           |
| 6.0             | 15              | 92              | 1.86                      | 56                            | 62                           |
| 6.5             | 7               | 98              | 3.48                      | 70                            | 61                           |
| 7.0             | 2               | 100             | 100                       | 60                            |                              |
| Fructosamine (mmol/L) |                 |                 |                           |                               |                              |
| (AUC 0.55 [0.47–0.63]; n = 222) |                 |                 |                           |                               |                              |
| 0               | 100             | 0               | 1.00                      | 40                            |                              |
| 1.25            | 71              | 29              | 0.99                      | 40                            | 59                           |
| 1.45            | 47              | 60              | 1.17                      | 44                            | 63                           |
| 1.65            | 24              | 88              | 2.08                      | 58                            | 63                           |
| 1.85            | 12              | 99              | 7.91                      | 84                            | 62                           |
| 2.05            | 6               | 100             | 100                       | 61                            |                              |
| Random glucose (mg/dL) |                 |                 |                           |                               |                              |
| (AUC 0.66 [0.60–0.73]; n = 243) |                 |                 |                           |                               |                              |
| 50              | 100             | 0               | 1.00                      | 40                            |                              |
| 60              | 99              | 1               | 1.00                      | 40                            | 50                           |
| 70              | 98              | 5               | 1.03                      | 41                            | 78                           |
| 80              | 97              | 17              | 1.17                      | 44                            | 89                           |
| 90              | 87              | 33              | 1.30                      | 47                            | 79                           |
| 100             | 55              | 67              | 1.66                      | 53                            | 69                           |
| 110             | 30              | 88              | 2.38                      | 62                            | 65                           |
| 120             | 14              | 96              | 3.45                      | 70                            | 62                           |
| 130             | 7               | 99              | 5.18                      | 78                            | 61                           |
| 140             | 3               | 99              | 4.44                      | 75                            | 60                           |
| 1-h OGTT (mg/dL) |                 |                 |                           |                               |                              |
| (AUC 0.68 [0.61–0.74]; n = 241) |                 |                 |                           |                               |                              |
| 60              | 100             | 0               | 1.00                      | 40                            |                              |
| 70              | 99              | 2               | 1.01                      | 41                            | 75                           |
| 80              | 96              | 11              | 1.08                      | 42                            | 80                           |
| 90              | 90              | 25              | 1.20                      | 45                            | 78                           |
| 100             | 77              | 42              | 1.34                      | 48                            | 73                           |
| 110             | 63              | 63              | 1.68                      | 53                            | 71                           |
| 120             | 44              | 81              | 2.28                      | 61                            | 68                           |
| 130             | 31              | 92              | 4.05                      | 73                            | 66                           |
| 140             | 21              | 92              | 2.70                      | 65                            | 63                           |
| 150             | 13              | 97              | 3.86                      | 72                            | 62                           |
| 160             | 9               | 98              | 4.45                      | 75                            | 62                           |
| 170             | 4               | 100             | 100                       | 61                            |                              |
developing diabetes, but because of convenience previous screening recommendations have prioritized the use of FPG. Studies have shown that a stimulated glucose is a better predictor than FPG of progression from IGT to diabetes (30). Furthermore, FPG will often miss cases of IGT and diabetes (31,32), further lending support for the use of random glucose or the 1-h GCT test in clinical practice.

Strengths of our study include the systematic evaluation of the performance of nonfasting tests in a pediatric population, the use of a gold standard 2-h OGTT for classifying children with dysglycemia, a reasonable study sample size, and the substantial proportion of minority children who were included in the study. We also acknowledge limitations of our study. According to the ADA, two positive tests are required to make a diagnosis of prediabetes or diabetes (20), and studies have reported a lack of reproducibility of the diagnosis of prediabetes using the 2-h OGTT in children (15). Therefore, children in our cohort with 2-h postload glucose levels >200 mg/dL may not have been classified as having diabetes if a second test had been performed, which could result in improvements in test performance. Although it would have been ideal to perform two 2-h OGTTs, we elected to perform one given the additional burden on participants. Furthermore, clinical research studies of adults, including the Diabetes Prevention Project (33), or the Screening for Impaired Glucose Tolerance Study (27), have classified participants’ glucose status using just one test.

With the new guidelines, HbA1c would now be considered the gold standard for diabetes, but studies have demonstrated significant differences in diabetes and prediabetes prevalence depending on the definition of diabetes used (FPG vs. 2-h postload glucose vs. HbA1c) (34). Although it may be logical to use a chronic measure of hyperglycemia such as HbA1c rather than an acute measure such as glucose, longitudinal studies in children are needed to understand which tests are most predictive of later development of diabetes. We elected to compare the nonfasting tests against the definitions of diabetes that have been historically used in the pediatric literature for purposes of comparability with other pediatric studies.

Our population was a convenience sample of overweight and obese children from southeast Michigan rather than a systematic sample from a well-defined target population. Although we had adequate representation of black and white children, there were no Hispanic children in the sample. Furthermore, given the sample size, we did not have the power to assess test performance according to each Tanner stage. Therefore, generalizations must be made accordingly. We had to power our study to the outcome of dysglycemia given the low prevalence of childhood diabetes. However, we note that this is reflective of the epidemiology of type 2 diabetes in the U.S., which still has a very low prevalence in the adolescent population (0.02%), particularly compared with adults (23). The ADA screening guidelines were established in 2000 (3) based on reports of dramatic increases in type 2 diabetes among adolescents, but subsequent population-based epidemiologic studies have not revealed a large burden of childhood type 2 diabetes. Identification of children with prediabetes, which has a much higher burden in the pediatric population, could be considered a useful by-product of diabetes screening, which would provide the opportunity for directing targeted interventions at children at highest risk for developing diabetes.

Because of the high burden of childhood obesity, the CDC estimates that approximately 2.3 million children in the U.S. potentially qualify for diabetes screening based on the ADA screening guidelines (35), highlighting the need for effective and practical strategies for screening. Random glucose and particularly 1-h GCT, given its possible greater predictive capacity for incident diabetes (36), represent promising screening tests for use in the pediatric primary care setting. Future studies are needed to assess the feasibility, acceptability, and cost-effectiveness of these alternative screening strategies compared with current recommendations and to assess the impact of systematic prediabetes and diabetes screening on pediatric health outcomes.

Acknowledgments—J.M.L. was supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (K08-DK-082386) and the Clinical Sciences Scholars Program at the University of Michigan. This project was supported by Michigan Clinical Research Unit Grant UL1RR024986, Michigan Institute for Clinical & Health Research Pilot and Collaborative Grant UL1RR024986, a Blue
Cross Blue Shield Foundation of Michigan Investigator Initiated Research grant, and grants from the University of Michigan (Elizabeth Kennedy Award/Elizabeth Crosby Funds/Office of the Vice President for Research). This study made use of the Laboratory core(s) of the Michigan Diabetes Research and Training Center Core Laboratories, funded by National Institutes of Health Grant 5P60-DK-20572 from the NIDDK.

No potential conflicts of interest relevant to this article were reported.

J.M.L. researched data, contributed to discussion, and wrote, reviewed, and edited the manuscript. A.G. researched data and reviewed and edited the manuscript. E.-L.W. and J.L. researched data and reviewed and edited the manuscript. J.G.G. contributed to discussion and reviewed and edited the manuscript.

Parts of this study were presented in abstract form at the 70th Scientific Sessions of the American Diabetes Association, Orlando, Florida, 25–29 June 2010.

References

1. Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr 1996;128:608–615
2. Lipton RB, Drum M, Burnet D, et al. Obesity at the onset of diabetes in an ethnically diverse population of children: what does it mean for epidemiologists and clinicians? Pediatrics 2005;115:e553–e560
3. American Diabetes Association. Type 2 diabetes in children and adolescents. Pediatrics 2000;105:671–680
4. Krebs NF, Himes JH, Jacobson D, Nicklas TA, Guilday P, Styne D. Assessment of child and adolescent overweight and obesity. Pediatrics 2007;120(Suppl. 4):S193–S228
5. Kaufman FR. Type 2 diabetes in children and youth. Rev Endocr Metab Disord 2003;4:33–42
6. Botero D, Wollsfeld JJ. Diabetes mellitus in children and adolescents. Arch Med Res 2005;36:281–290
7. Li C, Ford ES, Zhao G, Mokdad AH. Prevalence of pre-diabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among U.S. adolescents: National Health and Nutrition Examination Survey 2005-2006. Diabetes Care 2009;32:342–347
8. Nguyen QM, Srinivasan SR, Xu JH, Chen W, Berenson GS. Fasting plasma glucose levels within the normoglycemic range in childhood as a predictor of prediabetes and type 2 diabetes in adulthood: the Bogalusa Heart Study. Arch Pediatr Adolesc Med 2010;164:124–128
9. Rhodes ET, Finkelstein JA, Marshall R, Allen C, Gillman MW, Ludwig DS. Screening for type 2 diabetes mellitus in children and adolescents: attitudes, barriers, and practices among pediatric clinicians. Ambul Pediatr 2006;6:110–114
10. Anand SG, Mehta SD, Adams WG. Diabetes mellitus screening in pediatric primary care. Pediatrics 2006;118:1888–1895
11. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327–1334
12. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002;246:1–190
13. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19:708–723
14. Mooy JM, Grootenhuis PA, de Vries H, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996;39:298–305
15. Libman IM, Barnaas-Mitchell E, Bartucci A, Robertson R, Arslanian S. Reproducibility of the oral glucose tolerance test in overweight children. J Clin Endocrinol Metab 2008;93:4231–4237
16. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002;346:802–810
17. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009;32:287–294
18. Dolan LM, Bean J, D’Alessio D, et al. Frequency of abnormal carbohydrate metabolism and diabetes in a population-based screening of adolescents. J Pediatr 2005;146:751–758
19. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32(Suppl. 1):S62–S67
20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):S62–S69
21. Ziemer DC, Kolm P, Foster JK, et al. Random plasma glucose in serendipitous screening for glucose intolerance: screening for impaired glucose tolerance study 2. J Gen Intern Med 2008;23:528–535
22. Lee JM. Why young adults hold the key to assessing the obesity epidemic in children. Arch Pediatr Adolesc Med 2008;162:682–687
23. Liese AD, D’Agostino RB Jr, Hamman RF, et al.; SEARCH for Diabetes in Youth Study Group. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006;118:1510–1518
24. Lee JM, Wu EL, Tarini B, Herman WH, Yoon E. Diagnosis of diabetes using hemoglobin A1c: should recommendations in adults be extrapolated to adolescents? J Pediatr 2011;158:947–952
25. Nowicka P, Santoro N, Liu H, et al. Utility of hemoglobin A1c for diagnosing prediabetes and diabetes in obese children and adolescents. Diabetes Care 2011;34:1306–1311
26. Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS. Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care 2010;33:2184–2189
27. Phillips LS, Ziemer DC, Kolm P, et al. Glucose challenge test screening for prediabetes and undiagnosed diabetes. Diabetologia 2009;52:1798–1807
28. Carr SR. Screening for gestational diabetes mellitus. A perspective in 1998. Diabetes Care 1998;21(Suppl. 2):B14–B18
29. Engelgau MM, Aubert RE, Thompson TJ, Herman WH. Screening for NIDDM in nonpregnant adults. A review of principles, screening tests, and recommendations. Diabetes Care 1995;18:1606–1618
30. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997;46:701–710
31. Mannucci E, Bardini G, Ognibene A, Rotella CM. Screening for diabetes in obese patients using the new diagnostic criteria. Diabetes Care 1998;21:468–469
32. Barzilay JJ, Spiekerman CF, Wahl PW, et al. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 1999;354:622–625
33. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
34. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010;33:562–568
35. Fagot-Campagna A, Saaddine JB, Engelgau MM. Is testing children for type 2 diabetes a lost battle? Diabetes Care 2000;23:1442–1443
36. Abdul-Ghani MA, Stern MP, Lyssenko V, Tuomi T, Groop L, DeFronzo RA. Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose. Diabetes Care 2010;33:557–561